Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastomaW C Zamboni, A J Gajjar, T D Mandrell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecanM K Ma, W C Zamboni, K M Radomski, et al.CPT: Pharmacometrics & Systems Pharmacology|April 23, 2016
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric EpendymomaV M Daryani, Y T Patel, M Tagen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pharmacodynamic model of topotecan-induced time course of neutropeniaW C Zamboni, D Z D'Argenio, C F Stewart, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft modelsW C Zamboni, C F Stewart, P J Cheshire, et al.Bone Marrow Transplantation|October 19, 2001
Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cellsE J Yeoh, J M Cunningham, G C Yee, et al.The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretionW C Zamboni, P J Houghton, R K Johnson, et al.Journal of Pediatric Hematology/Oncology|November 1, 1996
Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group studyD G Tubergen, C F Stewart, C B Pratt, et al.Bone Marrow Transplantation|March 20, 2012
A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upK A Kasow, C F Stewart, R C Barfield, et al.Cancer Chemotherapy and Pharmacology|May 13, 1999
Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsW C Zamboni, L C Bowman, M Tan, et al.Pageof 9